Almirall has obtained approval from EC for EBGLYSS (lebrikizumab) to treat adult and adolescent patients with moderate-to-severe atopic dermatitis (AD).

Related Keywords

Switzerland , United Kingdom , Germany , Eli Lilly , Volker Koscielny , ,